EP0494995A1 - Cosmetic method of inhibiting the formation of a scar - Google Patents

Cosmetic method of inhibiting the formation of a scar

Info

Publication number
EP0494995A1
EP0494995A1 EP90916599A EP90916599A EP0494995A1 EP 0494995 A1 EP0494995 A1 EP 0494995A1 EP 90916599 A EP90916599 A EP 90916599A EP 90916599 A EP90916599 A EP 90916599A EP 0494995 A1 EP0494995 A1 EP 0494995A1
Authority
EP
European Patent Office
Prior art keywords
bond
hydrogen
proviso
vitamin
double bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90916599A
Other languages
German (de)
French (fr)
Other versions
EP0494995A4 (en
Inventor
Michael F. Holick
Xiao Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of EP0494995A1 publication Critical patent/EP0494995A1/en
Publication of EP0494995A4 publication Critical patent/EP0494995A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention is in the field of medicinal chemistry.
  • the present invention relates to novel methods for
  • Skin Human skin is a complex integration of different types of cells and tissues which form an organ. Skin is also the primary seat of the sense of touch and creates a covering for the protection of th ⁇ deeper tissues. The skin also plays an important role in the regulation of body temperature and is also an excretory and absorbing organ. Skin consists primarily of a layer of vascular tissue and an external covering of epithelium known as the epidermis. On the surface layer are the sensitive papillae and alongside or imbedded beneath it are certain specialized organs, specifically the sweat glands, hair follicles, and sebaceous glands.
  • wounds which are caused by physical means, result in a disruption of the normal continuity of the structures of the skin. Examples of wounds include cuts, punctures, lacerations, etc.
  • stomach lining is also composed of internal epithelium (endotheliu ).
  • Gastric ulcers are a result of damage or erosion of the stomach lining. Gastric ulcers occur along the lesser curvature of the stomach where the pyloric glands border the oxyntic gland. They are usually 1 to 2.5 cm in diameter; however, they can vary from a few mm to several cm. Ulcers are usually round, oval or elliptical, with sharply defined margins. The surrounding mucosa is often hyperemic and edematous. Ulcers penetrate into the submucosa or muscular layer.
  • a thin layer of gray or white exudate usually covers the base of the ulcers; this layer is composed of fibrinoid, granulation and fibrous tissue layers.
  • fibrous tissue in the base contracts the ulcer and may distort the surrounding tissue.
  • healing continues as granulation tissue fills the base and epithelium from the ulcer edges cover its surface.
  • the mechanism of epithelial wound healing is a complex process involving ultrastructural changes of epithelial cells. These changes allow for detachment from neighboring cells, migration and subsequent reattachment.
  • the migration of epithelial cells has been found to depend on a suitable matrix composed of fibrin, fibronectin or basement membrane which traverse the wound. Clark, R., J. Am. Acid Derm.. 13:701-718 (1985); Zitelli, J., Adv. Dermatol . 2:243-268 (1987).
  • the process involves clotting and formation of a crust or scab to seal the wound; an acute inflammatory reaction; reepithelialization of the surface and fibrous bridging due to fibrin followed by complete sealing of the wound by an epithelial covering. Thereafter, hair follicles, sebaceous glands and sweat glands may subsequently regenerate.
  • the process of second intention healing requires the removal of necrotic debris. The gap in the wound then fills in with fibrous materials.
  • carbenoxolene is used to treat gastric ulcers.
  • Carbenoxolene is a hydrolytic product of glycyrrhizic acid (derivativ of licorice); it has been shown to increase the rate of gastric ulce healing. Braunwald, E., Harrison's Principles of Internal Medicin 11th ed. p. 1247. It appears to increase the life span of gastri mucosal epithelial cells and increase the secretion and viscosity o gastric mucus.
  • carbenoxolene has aldosterone-like effects, therefore it tends to increase the rate at which the body retain sodium and water. These effects may be blocked by aldosterone antagonists, however the antagonists obliterate the healing effects o the carbenoxolene. There is a need for therapies which can promot healing without the negative side effects.
  • the skin may be a targe tissue for 1,25-(0H) -D3 (Stumpf, W.E. et al.. Science. 201:1188-119 (1979)).
  • Cells isolated from the skin of rats, mice, and humans, an from cultured human skin fibroblasts and keratinocytes contain a hig affinity (1.0 x 10 "10 M) low capacity receptor-like protein for 1,25 dihydroxyvitamin D3 (Franceschi, et al .. Arch. Biochem. Biophys. 210: 1-13 (1979); Simpson, R. U. et al., P.N.A.S. (USA). 77: 582 (1980); Colston, K. et al..
  • Holick, U.S. Patent No. 4,410,545 discloses vitamin D glycosides and their use in the regulation of calcium metabolism and phosphorous homeostasis.
  • Holick, U.S. Patent No. 4,521,410 discloses water-soluble glycosyl orthoesters of vitamin D and their use in the regulation of calcium metabolism and phosphorous homeostasis.
  • Calciphylaxis is a hypersensitivity reaction resulting from the administration of or endogenous production of a sensitizing calcifier in combination with a challenger.
  • Sensitizing calcifiers include, inter alia, vitamins D2 and D3.
  • Dikstein U.S. Patent No. 4,610,478, and European Patent Application No. 0 129003 (1984), discloses compositions containing 1- alpha-hydroxycholecalciferol or 1-alpha,25-dihydroxycholecalciferol for the topical treatment of skin disorders, such as dermatitis, psoriasis, eczema, solar keratosis and certain stages of wound healing and alopecia.
  • Dikstein also teaches that low dosages are required, from about 0.03 ⁇ g to 1.0 ⁇ g per gram of composition, to minimize the risk of undesired side effects and systemic effects.
  • Dikstein does not teach that vitamin D compounds are useful for the treatment of wounds caused by lacerations, punctures or cuts.
  • the invention relates to a method of enhancing the healing of wounds in a patient comprises administering to said patient an effective amount of a vitamin D compound, wherein said vitamin D compound has the Formula (I):
  • Y 1 is hydrogen, F, CH 3 , CH 2 CH 3 or X 1 ;
  • U is hydrogen, -OH or -0-(C2-C4 alkyl)-0H;
  • Zl is F, H or X 1 ;
  • Q a is CF 3 or CH2X 1 ;
  • Q b is CF 3 or CH 3 ;
  • R is a double bond or an epoxy group; wherein ⁇ l is selected from the group consisting of hydrogen and -OH; W is CH-CH3 or 0; and V is CH2 or 0; with the proviso that both W and V are not both 0; and
  • the invention also relates to a method of enhancing the healing of wounds in a patient which comprises administering to said patient an effective amount of a vitamin D compound, wherein said vitamin D compound has the
  • Y 2 is hydrogen, fluorine, methyl, ethyl or OR*;
  • Z 2 is F, H or X 2 ;
  • U is hydrogen, -OH or -0-(C -C4 alkyl)-0H;
  • Q a is CF 3 or CH 2 X 2 ;
  • Q b is CF 3 or CH3;
  • R is a double bond or an epoxy group
  • X 2 is selected from the group consisting of hydrogen
  • R! is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R! is an orthoester glycoside moiety of the Formula (III):
  • A represents a glucofuranosyl or glucopyranosyl ring
  • R 2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
  • R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, with the proviso that at least one of the R! is either a glycosidic residue or an orthoester glycoside moiety;
  • W is CH-CH3 or 0
  • V is CH 2 or 0; with the proviso that both W and V are not both 0;
  • the invention also relates to a method of inhibiting scar formation in a patient arising from cuts, lacerations, puncture wounds and abrasions which comprises administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (I):
  • Y 1 is hydrogen, F, CH 3 , CH 2 CH 3 or X 1 ;
  • U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
  • Z 1 is F, H or X 1 ;
  • Q a is CF 3 or CH 2 X ;
  • Q b is CF 3 or CH 3 ;
  • R is a double bond or an epoxy group; wherein ⁇ is selected from the group consisting of hydrogen and -OH;
  • W is CH-CH3 or 0; and with the proviso that both W and V are not both 0; and
  • the invention also relates to a method for inhibiting scar formation in a patient arising from cuts, lacerations, puncture wounds and abrasions which comprises topically administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (II):
  • Y 2 is hydrogen, fluorine, methyl, ethyl or OR 1 ;
  • U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
  • Z 2 is F, H or X 2 ;
  • Q a is CF 3 or CH 2 X 2 ;
  • Q b is CF 3 or CH 3 ;
  • R is a double bond or an epoxy group
  • X 2 is selected from the group consisting of hydrogen, and
  • R 1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R 1 is an orthoester glycoside moiety of the Formula (III):
  • A represents a glucofuranosyl or glucopyranosyl ring
  • R 2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
  • R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue;
  • W is CH-CH3 or 0
  • V is CH2 or 0; with the proviso that both W and V are not both 0;
  • the invention also relates to a method of treating gastric, duodenal, esophageal , decubitus, diabetic foot and genito-urinary ulcers in a patient which comprises administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (I):
  • Y 1 is hydrogen, F, CH 3 , CH 2 CH 3 or X 1 ;
  • U is hydrogen, -OH or -0-(C2-C4 alkyl)-0H;
  • Z 1 is F, H or X 1 ;
  • Q a is CF 3 or CH2X 1 ;
  • Q b is CF 3 or CH 3 ;
  • R is a double bond or an epoxy group; wherein X 1 is selected from the group consisting of hydrogen and -OH;
  • W is CH-CH3 or 0
  • V is CH2 or 0; with the proviso that both W and V are not both 0;
  • the invention also relates to a method for treating gastric, duodenal, esophageal, decubitus, diabetic foot, genito-urinary ulcers and ulcerative keratitis in a patient which comprises topically or ophthalmically administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (II):
  • Y 2 is hydrogen, fluorine, methyl, ethyl or ORl
  • U is hydrogen, -OH or -0-(C 2 -C4 alkyl)-OH;
  • Z 2 is F, H or X 2 ;
  • Q a is CF 3 or CH 2 X 2 ;
  • Q b is CF 3 or CH 3 ;
  • R is a double bond or an epoxy group
  • X 2 is selected from the group consisting of hydrogen, and
  • R 1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R 1 is an orthoester glycoside moiety of the Formula (III):
  • A represents a glucofuranosyl or glucopyranosyl ring
  • R 2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower 1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
  • R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue;
  • W is CH-CH3 or 0
  • V is CH 2 or 0; with the proviso that both W and V are not both 0;
  • Figure 1 depicts a graph showing the effect of vehicle and 5 ⁇ g, 10 ⁇ g, 27 ⁇ g and 54 ⁇ g of 1,25-dihydroxyvitamin D per gram of oil on the percentage of wound healing on days 1, 2, 3, 4, 5 and 6 in rats with experimental wounds.
  • Figure 2 depicts a graph showing the effect of vehicle and 27 ⁇ g 1,25-dihydroxyvitamin D3/gram oil on the percentage of wound healing on days 1, 2, 3, 4, 5 and 9 in rats with experimental wounds.
  • the present invention provides for a method of healing wounds and inhibiting scar formation.
  • Wounds to the external epithelium include cuts, punctures and lacerations, including corneal lacerations.
  • Wounds of the internal epithelium include peptic ulcers, esophageal mucosa injury, oral mucosa injuries and periodontal disease.
  • the invention also provides for the treatment of ulcers such as diabetic ulcers of the feet, decubitus ulcers (bed sores), genito-urinary ulcers, peptic ulcers and ulcerative keratitis. Ulcerative keratitis is caused, for example, by extended wear of contact lenses.
  • peptic ulcer includes both duodenal and gastric ulcers.
  • Peptic ulcers are a group of ulcerative disorders of the upper gastrointestinal tract; the primary forms of peptic ulcer are duodenal and gastric ulcer.
  • Normally gastric mucosa has the ability to resist the corrosive effects of acid-pepsin. This is a trait which is unique to the gastric mucosa; areas such as the esophagus do not have this ability.
  • Injury to the esophageal mucosa occurs from exposure to refluxed gastric juice and ulceration which occurs in the small intestine at the site of surgical attachment to actively secreting gastric mucosa.
  • Genito-urinary ulcers treatable with the vitamin D compounds of the invention ⁇ include those caused by, for example, herpes simplex virus as well as other viral, fungal and bacterial infections. See Harrison's Principles of Internal Medicine. E. Braunwald et al . (eds.); McGraw-Hill Book Co., New York, N.Y., 1987, pp. 514-516.
  • the vitamin D compounds of the invention may also be administered for the treatment of periodontal disease.
  • This disease begins as a marginal inflammation of the gingivae (gingivitis) which slowly spreads to involve the underlying alveolar bone and periodontal ligament.
  • the vitamin D compounds may be applied topically, for example, as part of a tooth paste formulation, or may be administered orally or part of a thin film implant between the teeth and gums to give sustained release of the vitamin D compound.
  • the film comprises a cellulose polymer. See U.S. Patent No. 4,315,779 to Heyd.
  • Y 1 is hydrogen, F, CH 3 , CH 2 CH 3 or X 1 ;
  • U is hydrogen, -OH or -0-(C 2 -C4 alkyl)-OH;
  • Z 1 is F, H or X 1 ;
  • R is a double bond or an epoxy group
  • X 1 is selected from the group consisting of hydrogen and -OH;
  • W is CH-CH3 or 0
  • V is CH2 or 0; with the proviso that both W and V are not both 0;
  • the compounds of Formula (I) When the compounds of Formula (I) have a double bond at position C-22, they are derivatives of vitamin D2, whereas if the bond at that position is single, and there is a lack of C24 alkyl, they are derivatives of vitamin D3. The latter are preferred.
  • vitamins D3 or D2 are vitamins D3 or D2; 1-hydrox vitamins D3 or D2; and 1,25-dihydroxyvitamins D3 or D2, 5,6-epoxy derivatives of vitamin D and its metabolites, 2- ⁇ -(3-hydroxypropoxy)-l alpha,25- dihydroxyvitamin D3, as well as the side chain fluoro derivatives of 1,25-(0H)2 vitamin D and 1-(0H) vitamin D.
  • 20- and 22-oxa vitamin D derivatives including 20-oxa-l ⁇ (0H)D, 20-oxa- l ⁇ ,25(0H) 2 D 3 , 22-oxa-l ⁇ (0H)D 3 and 22-oxa-l ⁇ ,25(0H)D 3 as well as pseudo-1-alpha-hydroxyvitamin D derivatives such as dihydrotachysterol and 5,6-trans vitamin D3 and their 25-hydroxy derivatives.
  • water soluble derivatives of the aforementioned compounds of Formula (I) obtained by solubilizing such compounds by attaching thetato glycosidic residues such as those disclosed in Holick, U.S. Patent 4,410,515.
  • Alternative methods of solubilization are by conjugating compounds of Formula (I) to glycosyl orthoester residues, as disclosed in copending U.S. S.N. 607,117 by Holick et al.. filed May 3, 1984.
  • the disclosures of the aforemen tioned patent and application are herein incorporated by reference an made a part hereof.
  • Y 2 is hydrogen, fluorine, methyl, ethyl or ORl
  • Z 2 is F, H or X 2 ;
  • U is hydrogen, -OH or -0-(C 2 -C4 alkyl)-OH;
  • R is a double bond or an epoxy group
  • X 2 is selected from the group consisting of hydrogen an OR 1 ;
  • R 1 is hydrogen or a straight or branched chain glycosidi residue containing 1-20 glycosidic units per residue, or R 1 is a orthoester glycoside moiety of the Formula (III):
  • A represents a glucofuranosyl or glucopyranosyl ring
  • R 2 is hydrogen, lower alkyl (C1-C4), aralkyl (C7-C10), or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl ;
  • R 3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue;
  • W is CH-CH3 or 0
  • V is CH2 or 0; with the proviso that both W and V are not both 0;
  • the vitamin D compounds are prepared or obtained according to the disclosures of the aforementioned references.
  • the 5,6- epoxy derivatives of vitamin D3 are obtained as described in Jpn. Kokai Tokkvo Koho JP 58,216,178 [83,216,178], Dec. 15, 1983.
  • the fluoro derivatives are made or obtained as described in Shiina, et al.. Arch. Biochem. Bioohvs 220:90 (1983).
  • Methods for preparing the 20- and 22-oxa vitamin D derivatives are disclosed by Abe, J., et al.. Vitamin D Molecular. Cellular and Clinical Endocrinology, p. 310-319, Walter de Gruyter & Co., Berlin (1988).
  • the compounds of the invention can be administered in any appropriate pharmaceutically acceptable carrier for oral, parenteral, or topical administration. They can be administered by any means that enhances wound healing, ulcer healing, amelioration of periodontal disease, and inhibition of scar formation in animals, especially humans.
  • the dosage administered will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.
  • systemic daily dosage of 1,25-dihydroxyvitamin D3 will be from about 0.001 micrograms/kg to 100 micrograms/kg preferably 0.01 to 1.0 micrograms per kg of body weight.
  • Dosage forms for topical administration include about 3 to 100 micrograms of 1,25-dihydroxyvitamin D3 per gram of carrier.
  • the dosage form contains about 5 ⁇ g to 3 mg of 1,25-dihydroxyvitamin D3 per gram of carrier. More preferably, the dosage form contains about 10 to 30 micrograms of 1,25-dihydroxyvitamin D3 per gram of carrier. A most preferred dosage form contains about 15 ug of 1,25-dihydroxyvitamin D3 per gram of carrier.
  • the compounds can be employed in dosage forms such as tablets, capsules, powder packets, or liquid solutions, suspensions or elixirs for oral administration, sterile liquid for formulations such as solutions or suspensions for parenteral use.
  • a pharmacologically inert topical carrier such as one comprising a gel, an ointment or a cream, including such carriers as water, glycerol, alcohol, propylene glycol, fatt alcohols, triglycerides, fatty acid esters or mineral oils.
  • liquid petroleum isopropylpalirritate, polyethy ⁇ lene glycol ethanol 95%, polyoxyethylene monolaurate 5% in water, sodium lauryl sulfate 5% in water, and the like.
  • Materials such as anti-oxidants, humectants, viscosity stabilizers and the like may be added, if necessary.
  • the compounds may also be present as part of a cosmetic formulation which may be formulated according to methods known to those of skill in the art. The compounds can also be administered by means of pumps, tapes or patches.
  • Rats were anesthetized with ether. Their backs were prepared by clipping and shaving. Two cutaneous wounds were made on each rat by punching on the right and left sides of the back with a sterile biopsy punch (diameter 4mm, wound thickness: full thickness of skin).
  • Control rats received vehicle only on wounds (20 ⁇ l vegetable oil/two wounds/day for 4 days).
  • the other four groups of rats (5 rats per group) were used to study the effect of 1,25(0H)2D3 on wound healing at different doses (5 ⁇ g l,25(0H)2D3/g oil, 10 ⁇ g/g oil, 27 ⁇ g/g oil and 54 ⁇ g/g oil 1,25 (0H)2D3). Treatment continued for up to 4 days.
  • Wound area was estimated by planimetry. For this purpose, the wound was covered with a transparent plastic film and wound outlines were drawn with a marker. Wound shape was then magnified, was cut out, and weighed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On a mis au point des procédés améliorant la cicatrisation de plaies, améliorant la cicatrisation d'ulcères gastriques, duodénaux, oesophagiens, de décubitus et génito-urinaires, et de la kératite ulcérative; inhibant la formation de cicatrices; et de traitement de maladies périodontiques chez l'animal par administration locale, orale, parentérale, transdermique ou ophtalmique d'un composé de vitamine D.Methods have been developed that improve wound healing, improve the healing of gastric, duodenal, esophageal, decubitus and genitourinary ulcers, and ulcerative keratitis; inhibiting the formation of scars; and treatment of periodontal diseases in animals by local, oral, parenteral, transdermal or ophthalmic administration of a vitamin D compound.

Description

TITLE OF THE INVENTION
METHOD OF ACCELERATING WOUND AND ULCER HEALING AND TREATING PERIODONTAL DISEASE
Field of the Invention
The invention is in the field of medicinal chemistry. In par¬ ticular, the present invention relates to novel methods for
« accelerating wound and ulcer healing and for treating periodontal disease using vitamin D-related compounds.
Brief Description of the Background Art
Human skin is a complex integration of different types of cells and tissues which form an organ. Skin is also the primary seat of the sense of touch and creates a covering for the protection of th ~deeper tissues. The skin also plays an important role in the regulation of body temperature and is also an excretory and absorbing organ. Skin consists primarily of a layer of vascular tissue and an external covering of epithelium known as the epidermis. On the surface layer are the sensitive papillae and alongside or imbedded beneath it are certain specialized organs, specifically the sweat glands, hair follicles, and sebaceous glands.
In order to defend the tissues below from trauma, the skin must be tough, flexible, and highly elastic. As a result of this function, injuries to the skin can occur. Wounds, which are caused by physical means, result in a disruption of the normal continuity of the structures of the skin. Examples of wounds include cuts, punctures, lacerations, etc.
Whereas skin is composed of an external covering of epithelium, the stomach lining is also composed of internal epithelium (endotheliu ). Gastric ulcers are a result of damage or erosion of the stomach lining. Gastric ulcers occur along the lesser curvature of the stomach where the pyloric glands border the oxyntic gland. They are usually 1 to 2.5 cm in diameter; however, they can vary from a few mm to several cm. Ulcers are usually round, oval or elliptical, with sharply defined margins. The surrounding mucosa is often hyperemic and edematous. Ulcers penetrate into the submucosa or muscular layer. A thin layer of gray or white exudate usually covers the base of the ulcers; this layer is composed of fibrinoid, granulation and fibrous tissue layers. During healing, fibrous tissue in the base contracts the ulcer and may distort the surrounding tissue. Healing continues as granulation tissue fills the base and epithelium from the ulcer edges cover its surface.
Healing usually requires two to six weeks but may require a longer time, especially if the ulcer is large or of a longstanding nature. If complete healing of the ulcer does not occur (as monitored by X-ray or endoscopic exam), surgery is usually considered in an effort to prevent complications or a prolonged, distressing course. The Merck Manual of Diagnosis and Therapy. 14th ed., by Merck Sharp & Dohme Research Laboratories (1982).
The mechanism of epithelial wound healing is a complex process involving ultrastructural changes of epithelial cells. These changes allow for detachment from neighboring cells, migration and subsequent reattachment. The migration of epithelial cells has been found to depend on a suitable matrix composed of fibrin, fibronectin or basement membrane which traverse the wound. Clark, R., J. Am. Acid Derm.. 13:701-718 (1985); Zitelli, J., Adv. Dermatol . 2:243-268 (1987). There are two types of healing processes: (1) primary union or first intention healing and (2) secondary union or second intention healing. Primary union occurs when a clean wound with a minimal loss of tissue heals together cleanly. The process involves clotting and formation of a crust or scab to seal the wound; an acute inflammatory reaction; reepithelialization of the surface and fibrous bridging due to fibrin followed by complete sealing of the wound by an epithelial covering. Thereafter, hair follicles, sebaceous glands and sweat glands may subsequently regenerate. The process of second intention healing requires the removal of necrotic debris. The gap in the wound then fills in with fibrous materials.
When dealing with gastric ulcers the major objectives of therapy are relief of pain and healing of the ulcer. In a number of countries (not the U.S.) carbenoxolene is used to treat gastric ulcers. Carbenoxolene is a hydrolytic product of glycyrrhizic acid (derivativ of licorice); it has been shown to increase the rate of gastric ulce healing. Braunwald, E., Harrison's Principles of Internal Medicin 11th ed. p. 1247. It appears to increase the life span of gastri mucosal epithelial cells and increase the secretion and viscosity o gastric mucus. However, carbenoxolene has aldosterone-like effects, therefore it tends to increase the rate at which the body retain sodium and water. These effects may be blocked by aldosterone antagonists, however the antagonists obliterate the healing effects o the carbenoxolene. There is a need for therapies which can promot healing without the negative side effects.
It has recently become clear that the skin may be a targe tissue for 1,25-(0H) -D3 (Stumpf, W.E. et al.. Science. 201:1188-119 (1979)). Cells isolated from the skin of rats, mice, and humans, an from cultured human skin fibroblasts and keratinocytes contain a hig affinity (1.0 x 10"10 M) low capacity receptor-like protein for 1,25 dihydroxyvitamin D3 (Franceschi, et al .. Arch. Biochem. Biophys. 210: 1-13 (1979); Simpson, R. U. et al., P.N.A.S. (USA). 77: 582 (1980); Colston, K. et al.. Endocrinology. 107: 1916 (1980); Feldman D. et al.. Journal of Clinical Endocrinology & Metabolism. 51.: 1463 (1980); Ell, C. et al.. P.N.A.S. (USA). 78: 2562 (1981); and Clemens, T.L. et al .. J. Clin. Endocr. Metab. 56: April 1983)). A specific biological function for 1,25-(OH)2 -vitamin D3 in the skin, however, has yet to be discovered. Nevertheless, evidence has come forth supporting the concept that the dihydroxy metabolite of the vitamin does have biologic actions in the skin. This evidence was obtained evaluating the biological activity of 1,25-dihydroxy vitamin D3 simultaneously in cultured human skin fibroblasts that either pos¬ sessed or lacked a cytosolic receptor-like protein for the hormone (Clemens, T. L. et al ., J. Clin Endocrino! . Metab.. 56: April 1983). The receptor-negative skin fibroblasts were obtained from a patient with a rare bone disorder called vitamin D dependent rickets, type II, a heritable disorder caused by a defective or complete absence of a cytop.asmic or nuclear receptor for 1,25-dihydroχγvitamin D. Administration of the dihydroxy metabolite of vitamin D3 caused a dose-dependent inhibition of cell growth in receptor positive skin fibroblasts (about 40-50% reduction in cell growth was observed in cultures containing 10"6 and 10"** M of hormone and 12% in cultures containing 10"1° M of l,25-(OH)2-D3), and, by contrast, had absolutely no effect on the growth of receptor negative skin fibroblasts.
Holick et al . (New England Journal of Medicine. 303:349-354 (1980)) have studied the feasibility of using the skin as an organ for the synthesis and absorption of vitamin D metabolites. These investigators demonstrated that topical application of various vitamin D metabolites or pro-vitamin forms followed by phototherapy results in elevated serum levels of dihydroxyvitamin D3. It was therefore suggested that topical application of vitamin D analogues may be an effective method of therapy for diseases involving calcium, phosphor¬ ous and bone metabolism problems.
Holick, U.S. Patent No. 4,410,515, discloses vitamin D glycosides and their use in the regulation of calcium metabolism and phosphorous homeostasis. Holick, U.S. Patent No. 4,521,410, discloses water-soluble glycosyl orthoesters of vitamin D and their use in the regulation of calcium metabolism and phosphorous homeostasis.
Holick, U.S. Patent No. 4,335,120, discloses that the toxic effects of orally administered vitamin D2 and vitamin D3 compounds can be avoided by topical administration whereby a slow and controlled transportation of the vitamin D compounds into the blood stream of a subject is achieved.
Jackson, U.S. Patent No. 3,655,881 (1972) discloses methods for treating burned skin by inducing a state of calciphylaxis. Calciphylaxis is a hypersensitivity reaction resulting from the administration of or endogenous production of a sensitizing calcifier in combination with a challenger. Sensitizing calcifiers include, inter alia, vitamins D2 and D3.
Dikstein, U.S. Patent No. 4,610,478, and European Patent Application No. 0 129003 (1984), discloses compositions containing 1- alpha-hydroxycholecalciferol or 1-alpha,25-dihydroxycholecalciferol for the topical treatment of skin disorders, such as dermatitis, psoriasis, eczema, solar keratosis and certain stages of wound healing and alopecia. Dikstein also teaches that low dosages are required, from about 0.03 μg to 1.0 μg per gram of composition, to minimize the risk of undesired side effects and systemic effects. However, Dikstein does not teach that vitamin D compounds are useful for the treatment of wounds caused by lacerations, punctures or cuts.
Additionally, no specific therapy is available for healing decubitus or diabetic ulcers of the feet, however it is suggested that a course of aggressive supportive treatment can lead to salvagin the limb. Therefore, a need exists for effective treatments fo diabetic ulcers. SUMMARY OF THE INVENTION
Despite the teaching of Dikstein high doses of 1-alpha- hydroxycholecalciferol or l-alpha,25-dihydroxycholecalciferol must be avoided, the inventors have discovered that the administration of relatively high levels of active vitamin D compounds and homologues, analogues, and hydroxylated metabolites thereof are therapeutically useful, in particular, for the treatment of wounds, ulcers, and periodontal disease.
In particular, the invention relates to a method of enhancing the healing of wounds in a patient comprises administering to said patient an effective amount of a vitamin D compound, wherein said vitamin D compound has the Formula (I):
wherein the bond between carbons C-22 and C-23 is single or double bond;
Y1 is hydrogen, F, CH3, CH2CH3 or X1; U is hydrogen, -OH or -0-(C2-C4 alkyl)-0H;
Zl is F, H or X1;
Qa is CF3 or CH2X1;
Qb is CF3 or CH3;
R is a double bond or an epoxy group; wherein χl is selected from the group consisting of hydrogen and -OH; W is CH-CH3 or 0; and V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and QD or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then χl is H.
The invention also relates to a method of enhancing the healing of wounds in a patient which comprises administering to said patient an effective amount of a vitamin D compound, wherein said vitamin D compound has the
wherein the bond between C-22 and C-23 is a single or double bond;
Y2 is hydrogen, fluorine, methyl, ethyl or OR*;
Z2 is F, H or X2;
U is hydrogen, -OH or -0-(C -C4 alkyl)-0H;
Qa is CF3 or CH2X2;
Qb is CF3 or CH3;
R is a double bond or an epoxy group; X2 is selected from the group consisting of hydrogen, and
OR1,
R! is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R! is an orthoester glycoside moiety of the Formula (III):
wherein A represents a glucofuranosyl or glucopyranosyl ring;
R2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, with the proviso that at least one of the R! is either a glycosidic residue or an orthoester glycoside moiety;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and QD or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X2 is H.
The invention also relates to a method of inhibiting scar formation in a patient arising from cuts, lacerations, puncture wounds and abrasions which comprises administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (I):
wherein the bond between carbons C-22 and C-23 is single or double bond;
Y1 is hydrogen, F, CH3, CH2CH3 or X1;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Z1 is F, H or X1;
Qa is CF3 or CH2X ;
Qb is CF3 or CH3;
R is a double bond or an epoxy group; wherein χ is selected from the group consisting of hydrogen and -OH;
W is CH-CH3 or 0; and with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and QD or a hydrogen atom on Qa and QD, with the proviso that wherein "===" is a single bond, then X* is H.
The invention also relates to a method for inhibiting scar formation in a patient arising from cuts, lacerations, puncture wounds and abrasions which comprises topically administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (II):
wherein the bond between C-22 and C-23 is a single or double bond;
Y2 is hydrogen, fluorine, methyl, ethyl or OR1;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Z2 is F, H or X2;
Qa is CF3 or CH2X2;
Qb is CF3 or CH3;
R is a double bond or an epoxy group;
X2 is selected from the group consisting of hydrogen, and
ORl;
R1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R1 is an orthoester glycoside moiety of the Formula (III):
wherein A represents a glucofuranosyl or glucopyranosyl ring;
R2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and Qb or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X2 is H.
The invention also relates to a method of treating gastric, duodenal, esophageal , decubitus, diabetic foot and genito-urinary ulcers in a patient which comprises administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (I):
wherein the bond between -carbons C-22 and C-23 is single or double bond;
Y1 is hydrogen, F, CH3, CH2CH3 or X1; U is hydrogen, -OH or -0-(C2-C4 alkyl)-0H;
Z1 is F, H or X1;
Qa is CF3 or CH2X1;
Qb is CF3 or CH3;
R is a double bond or an epoxy group; wherein X1 is selected from the group consisting of hydrogen and -OH;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===M is either a single bond between Qa and Qb or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X1 is H.
The invention also relates to a method for treating gastric, duodenal, esophageal, decubitus, diabetic foot, genito-urinary ulcers and ulcerative keratitis in a patient which comprises topically or ophthalmically administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (II):
wherein the bond between C-22 and C-23 is a single or double bond; Y2 is hydrogen, fluorine, methyl, ethyl or ORl;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Z2 is F, H or X2;
Qa is CF3 or CH2X2;
Qb is CF3 or CH3;
R is a double bond or an epoxy group;
X2 is selected from the group consisting of hydrogen, and
OR1;
R1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R1 is an orthoester glycoside moiety of the Formula (III):
wherein A represents a glucofuranosyl or glucopyranosyl ring;
R2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower 1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and Q or a hydrogen atom on Qa and Q , with the proviso that wherein "===" is a single bond, then X2 is H. DESCRIPTION OF THE FIGURES
Figure 1 depicts a graph showing the effect of vehicle and 5 μg, 10 μg, 27 μg and 54 μg of 1,25-dihydroxyvitamin D per gram of oil on the percentage of wound healing on days 1, 2, 3, 4, 5 and 6 in rats with experimental wounds.
Figure 2 depicts a graph showing the effect of vehicle and 27 μg 1,25-dihydroxyvitamin D3/gram oil on the percentage of wound healing on days 1, 2, 3, 4, 5 and 9 in rats with experimental wounds.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention provides for a method of healing wounds and inhibiting scar formation. Wounds to the external epithelium include cuts, punctures and lacerations, including corneal lacerations. Wounds of the internal epithelium include peptic ulcers, esophageal mucosa injury, oral mucosa injuries and periodontal disease. The invention also provides for the treatment of ulcers such as diabetic ulcers of the feet, decubitus ulcers (bed sores), genito-urinary ulcers, peptic ulcers and ulcerative keratitis. Ulcerative keratitis is caused, for example, by extended wear of contact lenses.
As used herein, the term "peptic ulcer" includes both duodenal and gastric ulcers. Peptic ulcers are a group of ulcerative disorders of the upper gastrointestinal tract; the primary forms of peptic ulcer are duodenal and gastric ulcer. Normally gastric mucosa has the ability to resist the corrosive effects of acid-pepsin. This is a trait which is unique to the gastric mucosa; areas such as the esophagus do not have this ability. Injury to the esophageal mucosa occurs from exposure to refluxed gastric juice and ulceration which occurs in the small intestine at the site of surgical attachment to actively secreting gastric mucosa. Genito-urinary ulcers treatable with the vitamin D compounds of the invention^ include those caused by, for example, herpes simplex virus as well as other viral, fungal and bacterial infections. See Harrison's Principles of Internal Medicine. E. Braunwald et al . (eds.); McGraw-Hill Book Co., New York, N.Y., 1987, pp. 514-516.
The vitamin D compounds of the invention may also be administered for the treatment of periodontal disease. This disease begins as a marginal inflammation of the gingivae (gingivitis) which slowly spreads to involve the underlying alveolar bone and periodontal ligament. See Harrison's Principals of Internal Medicine, supra, pp. 164. The vitamin D compounds may be applied topically, for example, as part of a tooth paste formulation, or may be administered orally or part of a thin film implant between the teeth and gums to give sustained release of the vitamin D compound. Preferably, the film comprises a cellulose polymer. See U.S. Patent No. 4,315,779 to Heyd.
Among the preferred compounds usable in the present invention are those of the formula (I):
wherein the bond between carbons C-22 and C-23 is single or double;
Y1 is hydrogen, F, CH3, CH2CH3 or X1;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Z1 is F, H or X1;
R is a double bond or an epoxy group;
X1 is selected from the group consisting of hydrogen and -OH;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===•• is either a single bond between Qa and Qb or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X1 is H.
When the compounds of Formula (I) have a double bond at position C-22, they are derivatives of vitamin D2, whereas if the bond at that position is single, and there is a lack of C24 alkyl, they are derivatives of vitamin D3. The latter are preferred.
Preferred are those compounds derived from vitamins D3 or D2; 1- hydroxyvitamins D3 or D2; 1,24-dihydroxyvitamins D2 and D3; 1,25- dihydroxyvitamins D3 and D2; 24,25-dihydroxyvitamins D3 or D2; 25,26- hydroxyvitamins D3 or D2; 1,24,25-trihydrox vitamins D3 or D2. Most preferred among these are vitamins D3 or D2; 1-hydrox vitamins D3 or D2; and 1,25-dihydroxyvitamins D3 or D2, 5,6-epoxy derivatives of vitamin D and its metabolites, 2-β-(3-hydroxypropoxy)-l alpha,25- dihydroxyvitamin D3, as well as the side chain fluoro derivatives of 1,25-(0H)2 vitamin D and 1-(0H) vitamin D. Also preferred are 20- and 22-oxa vitamin D derivatives including 20-oxa-lα(0H)D, 20-oxa- lα,25(0H)2D3, 22-oxa-lα(0H)D3 and 22-oxa-lα,25(0H)D3 as well as pseudo-1-alpha-hydroxyvitamin D derivatives such as dihydrotachysterol and 5,6-trans vitamin D3 and their 25-hydroxy derivatives.
Among other preferred compounds are water soluble derivatives of the aforementioned compounds of Formula (I) obtained by solubilizing such compounds by attaching thetato glycosidic residues such as those disclosed in Holick, U.S. Patent 4,410,515. Alternative methods of solubilization are by conjugating compounds of Formula (I) to glycosyl orthoester residues, as disclosed in copending U.S. S.N. 607,117 by Holick et al.. filed May 3, 1984. The disclosures of the aforemen tioned patent and application are herein incorporated by reference an made a part hereof.
Also useful in the practice of the invention are compounds of th Formula (II):
wherein Y2 is hydrogen, fluorine, methyl, ethyl or ORl;
Z2 is F, H or X2;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Qa and QD have the same meanings as in Formula (I);
R is a double bond or an epoxy group;
X2 is selected from the group consisting of hydrogen an OR1;
R1 is hydrogen or a straight or branched chain glycosidi residue containing 1-20 glycosidic units per residue, or R1 is a orthoester glycoside moiety of the Formula (III):
wherein A represents a glucofuranosyl or glucopyranosyl ring;
R2 is hydrogen, lower alkyl (C1-C4), aralkyl (C7-C10), or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl ;
R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and Qb or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X2 is H; and with the further proviso that at least one of the R1 is either a glycosidic residue or an orthoester glycoside moiety.
The vitamin D compounds are prepared or obtained according to the disclosures of the aforementioned references. In particular, the 5,6- epoxy derivatives of vitamin D3 are obtained as described in Jpn. Kokai Tokkvo Koho JP 58,216,178 [83,216,178], Dec. 15, 1983. The fluoro derivatives are made or obtained as described in Shiina, et al.. Arch. Biochem. Bioohvs 220:90 (1983). Methods for preparing the 20- and 22-oxa vitamin D derivatives are disclosed by Abe, J., et al.. Vitamin D Molecular. Cellular and Clinical Endocrinology, p. 310-319, Walter de Gruyter & Co., Berlin (1988). U.S. Patent No. 4,719,205 to DeLuca et al . discloses methods for the preparation of 22,23-cis- unsaturated, 1-hydroxyvitamin D compounds. U.S. Patent No. 4,634,692 to Partridge et al. discloses methods for the preparation of 1,25- dihydroxy-24 (R or S)-fluorovitamin D. Japanese Patent Application, publication no. J55 111-460, discloses methods for the preparation of 24,24-difluoro-25-hydroxyvitamin D3.
The compounds of the invention can be administered in any appropriate pharmaceutically acceptable carrier for oral, parenteral, or topical administration. They can be administered by any means that enhances wound healing, ulcer healing, amelioration of periodontal disease, and inhibition of scar formation in animals, especially humans. The dosage administered will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired. For example, systemic daily dosage of 1,25-dihydroxyvitamin D3 will be from about 0.001 micrograms/kg to 100 micrograms/kg preferably 0.01 to 1.0 micrograms per kg of body weight. Normally, from 0.1 to 100 micrograms/kg per day of 1,25-dihydroxyvitamin D3, in one or more dosages per day is effective to obtain the desired results. Dosage forms for topical administration include about 3 to 100 micrograms of 1,25-dihydroxyvitamin D3 per gram of carrier. Preferably, the dosage form contains about 5 μg to 3 mg of 1,25-dihydroxyvitamin D3 per gram of carrier. More preferably, the dosage form contains about 10 to 30 micrograms of 1,25-dihydroxyvitamin D3 per gram of carrier. A most preferred dosage form contains about 15 ug of 1,25-dihydroxyvitamin D3 per gram of carrier. One of ordinary skill in the art can determine the optimal dosages and concentrations of other active vitamin D compounds with only routine experimentation.
The compounds can be employed in dosage forms such as tablets, capsules, powder packets, or liquid solutions, suspensions or elixirs for oral administration, sterile liquid for formulations such as solutions or suspensions for parenteral use. Alternatively, the compounds can be present in a pharmacologically inert topical carrier such as one comprising a gel, an ointment or a cream, including such carriers as water, glycerol, alcohol, propylene glycol, fatt alcohols, triglycerides, fatty acid esters or mineral oils. Other possible carriers are liquid petroleum, isopropylpalirritate, polyethy¬ lene glycol ethanol 95%, polyoxyethylene monolaurate 5% in water, sodium lauryl sulfate 5% in water, and the like. Materials such as anti-oxidants, humectants, viscosity stabilizers and the like may be added, if necessary. The compounds may also be present as part of a cosmetic formulation which may be formulated according to methods known to those of skill in the art. The compounds can also be administered by means of pumps, tapes or patches.
Having now generally described this invention, the same will be understood by reference to the following examples which are provided herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.
EXAMPLES
Example 1 The Effects of 1.25.0H)2D3 on Wound Healing in Rats
Materials:
25 CD rats 8 weeks old were obtained from Charles River Laboratories, Inc., Wilmington, MA.
Wounding Procedure:
Rats were anesthetized with ether. Their backs were prepared by clipping and shaving. Two cutaneous wounds were made on each rat by punching on the right and left sides of the back with a sterile biopsy punch (diameter 4mm, wound thickness: full thickness of skin).
Control rats received vehicle only on wounds (20 μl vegetable oil/two wounds/day for 4 days). The other four groups of rats (5 rats per group) were used to study the effect of 1,25(0H)2D3 on wound healing at different doses (5 μg l,25(0H)2D3/g oil, 10 μg/g oil, 27 μg/g oil and 54 μg/g oil 1,25 (0H)2D3). Treatment continued for up to 4 days.
Measurement Procedure:
Wound area was estimated by planimetry. For this purpose, the wound was covered with a transparent plastic film and wound outlines were drawn with a marker. Wound shape was then magnified, was cut out, and weighed.
Healing was assessed as the decrease in wound area on days 2, 3, 4, 5 and 6. The results are shown in Table 1 below and is depicted in Figure 1. The data (percent healing on day 2, 3, 4, 5 and 6) were analyzed for significance using students T test. In order to confirm the effectiveness of 1,25-(0H)2D3 in promoting wound healing, a second experiment was carried out using eight rats (dose of 1,25(0H) D3 = 27 ug/g oil). The results are depicted in Figure 2.
Results:
As can be seen clearly in Figures 1 and 2, topical administration of 1,25(0H)2U3 enhanced substantially the healing of puncture wounds in rats. The extent of wound healing was directly related to the concentration of 1,25(0H)2D3 in oil applied to the wound. These results demonstrate conclusively that vitamin D compounds are useful for enhancing wound healing in individuals.
Table 1 EFFECT OF 1,25(0H)2D3 ON WOUND HEALING OF RATS
% HEALING3
GROUP DAY 2 DAY 3 DAY 4 DAY 5 DAY 6
a. % HEALING = Original Wound Area b. MEANS±SEM, n-10
Significance of difference from control using Student's t test: * p<.05, § p<.025 and # p<.005

Claims

WHAT IS CLAIMED AS NEW IS:
1. A method of enhancing wound healing in an animal which comprises administering to said animal an effective amount of a vitamin D compound, wherein said vitamin D compound has the formula:
wherein the bond between carbons C-22 and C-23 is single o double bond;
Y1 is hydrogen, F, CH3, CH CH3 or X1;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Z1 is F, H or X1;
Qa is CF3 or CH2X1;
Qb is CF3 or CH3;
R is a double bond or an epoxy group;
X1 is selected from the group consisting of hydrogen and -OH;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and Qb or a hydroge atom on Qa and Q , with the proviso that wherein "===" is a singl bond, then X1 is H. 2. The method of claim 1, wherein said bond between carbons C-
22 and C-23 is a single bond and X1 is hydrogen.
3. The method of claim 1, wherein said bond between C-22 and C-
23 is a single bond, X1 is hydroxyl, and at least one of the group consisting of Y1, Z1, Qa and Qb contains a fluorine atom.
4. The method of claim 1, wherein said bond between C-22 and C- 23 is a double bond.
5. The method of claim 1, wherein said bond between C-22 and C- 23 is a double bond and X1 is hydrogen.
6. The method of claim 1, wherein said bond between C-22 and C- 23 is a double bond and X1 is hydroxyl.
7. A method of enhancing wound healing in an animal which comprises administering to said animal an effective amount of a vitamin D compound, wherein said vitamin D compound has the formula:
wherein the bond between C-22 and C-23 is a single or double bond; Y2 is hydrogen, fluorine, methyl, ethyl or ORl;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Z2 is F, H or X2;
Qa is CF3 or CH2X2;
Qb is CF3 or CH3;
R is a double bond or an epoxy group;
X2 is selected from the group consisting of hydrogen and
OR1, wherein R1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R1 is an orthoester glycoside moiety of the formula:
wherein A represents a glucofuranosyl or glucopyranosyl ring;
R2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, with the provis that at least one of the R1 is either a glycosidic residue or a orthoester glycoside moiety;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and "===" s either a single bond between Qa and Qb or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X2 is H.
8. The method of claim 7, wherein said bond between C-22 and C- 23 is a single bond and at least one of the group consisting of Y2, Z2, Qa and Qb contains a fluorine atom.
9. The method of claim 1 or 7, wherein said pharmaceutical composition is applied topically.
10. A method of inhibiting scar formation in an animal, wherein said scar may arise from a cut, puncture wound, laceration, or abrasion, which comprises administering to said animal an effective amount of a vitamin D compound, wherein said vitamin D compound has the formula:
wherein the bond between carbons C-22 and C-23 is single or double bond; Y1 is hydrogen, F, CH3, CH2CH3 or X1;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Z1 is F, H or X1;
Qa is CF3 or CH2X1;
Qb is CF3 or CH3;
R is a double bond or an epoxy group;
X1 is selected from the group consisting of hydrogen and -OH;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and Qb or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X1 is H.
11. The method of claim 10, wherein said bond between carbons C- 22 and C-23 is a single bond and X1 is hydrogen.
12. The method of claim 10, wherein said bond between C-22 and C-23 is a single bond, X1 is hydroxyl, and at least one of the group consisting of Y1, Z1, Qa and Qb contains a fluorine atom.
13. The method of claim 10, wherein said bond between C-22 and C-23 is a double bond.
14. The method of claim 10, wherein said bond between C-22 and C-23 is a double bond and X1 is hydrogen.
15. The method of claim 10, wherein said bond between C-22 and C-23 is a double bond and X1 is hydroxyl.
16. A method of inhibiting scar formation in an animal, wherein said scar may arise from a cut, puncture wound, laceration or abrasion, which comprises administering to said animal an effective amount of a vitamin D compound, wherein said vitamin D compound has the formula:
wherein the bond between C-22 and C-23 is a single or double bond;
Y2 is hydrogen, fluorine, methyl, ethyl or OR1;
U is hydrogen, -OH or -0-(C2~C4 alkyl)-OH;
Z2 is F, H or X2;
Qa is CF3 or CH2X2;
Qb is CF3 or CH3;
R is a double bond or an epoxy group;
X2 is selected from the group consisting of hydrogen and
OR1, wherein R1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R1 is an orthoester glycoside moiety of the formula:
wherein A represents a glucofuranosyl or glucopyranosyl ring; R2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, with the proviso that at least one of the R1 is either a glycosidic residue or an orthoester glycoside moiety;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and Q or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X2 is H.
17. The method of claim 16, wherein said bond between C-22 and C-23 is a single bond and at least one of the group consisting of Y2, Z2, Qa and Qb contains a fluorine atom.
18. The method of claim 10 or 16, wherein said pharmaceutical composition is administered by topical means.
19. A method of treating gastric, duodenal, esophageal, decubitus, genito-urinary ulcers, diabetic foot ulcers or ulcerative keratitis in an animal which comprises administering to said animal a pharmaceutical composition comprising a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the formula:
wherein the bond between C-22 and C-23 is a single or double bond;
Y1 is hydrogen, F, CH3, CH2CH3 or X1; U is hydrogen, -OH or -0-(C2-C4 alkyl)-0H; Z1 is F, H or X1; Qa is CF3 or CH2X1; Qb is CF3 or CH3;
R is a double bond or an epoxy group; X1 is selected from the group consisting of hydrogen and -OH; W is CH-CH3 or 0; and V is CH2 or 0; with the proviso that both W and V are not both 0; and
"._.==" is either a single bond between Qa and Q or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X1 is H.
20. The method of claim 19, wherein said bond between carbons C- 22 and C-23 is a single bond and X1 is hydrogen.
21. The method of claim 19, wherein said bond between C-22 and C-23 is a single bond, X1 is hydroxyl, and at least one of the group consisting of Y1, Z1, Qa and Qb contains a fluorine atom.
22. The method of claim 19, wherein said bond between C-22 and C-23 is a double bond.
23. The method of claim 19, wherein said bond between C-22 and C-23 is a double bond and X1 is hydrogen.
24. The method of claim 19, wherein said bond between C-22 and C-23 is a double bond and X1 is hydroxyl.
25. A method of treating gastric, duodenal, esophageal, decubitus, genital-urinary, diabetic foot ulcers or ulcerative keratitis in an animal which comprises administering to said animal a pharmaceutical composition comprising a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the formula:
wherein the bond between C-22 and C-23 is a single or double bond;
Y2 is hydrogen, fluorine, methyl, ethyl or OR1;
Z2 is F, H or X2;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Qa is CF3 or CH2X2;
Qb is CF3 or CH3;
R is a double bond or an epoxy group;
X2 is selected from the group consisting of hydrogen, and
OR1, wherein R1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R1 is an orthoester glycoside moiety of the formula:
wherein A represents a glucofuranosyl or glucopyranosyl ring;
R2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, with the proviso that at least one of the R1 is either a glycosidic residue or an orthoester glycoside moiety;
W is CH-CH3 or 0; and
V is CH2 or 0; with the proviso that both W and V are not both 0; and
"»=" is either a single bond between Qa and Qb or a hydrogen atom on Qa and Qb, with the proviso that wherein "===" is a single bond, then X2 is H.
26. The method of claim 2ϋ, wherein said bond between C-22 and C-23 is a single bond and at least one of the group consisting of Y2, Z2, Qa and Qb contains a fluorine atom.
27. A method of treating periodontal disease in an animal which comprises administering to said animal a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the formula:
wherein the bond between C-22 and C-23 is a single or double bond;
Y1 is hydrogen, F, CH3, CH2CH3 or X1;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Z1 is F, H or X1;
Qa is CF3 or CH2X1;
Qb is CF3 or CH3;
R is a double bond or an epoxy group; X1 is selected from the group consisting of hydrogen and -OH; W is CH-CH3 or 0; and V is CH2 or 0; with the proviso that both W and V are not both 0; and
"===" is either a single bond between Qa and Q or a hydrogen atom on Qa and QD, with the proviso that wherein "===" is a single bond, then X1 is H.
28. The method of claim 27, wherein said bond between carbons C- 22 and C-23 is a single bond and X1 is hydrogen.
29. The method of claim 27, wherein said bond between C-22 and C-23 is a single bond, X1 is hydroxyl, and at least one of the group consisting of Y1, Z1, Qa and Q contains a fluorine atom.
30. The method of claim 27, wherein said bond between C-22 and C-23 is a double bond.
31- The method of claim 27, wherein said bond between C-22 and C-23 is a double bond and X1 is hydrogen.
32. The method of claim 27, wherein said bond between C-22 and C-23 is a double bond and X1 is hydroxyl.
33. A method of treating periodontal disease in an animal which comprises administering to said animal a pharmaceutical composition comprising a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the formula:
wherein the bond between C-22 and C-23 is a single or double bond;
Y2 is hydrogen, fluorine, methyl, ethyl or OR1;
U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
Z2 is F, H or X2;
Qa is CF3 or CH2X2;
Qb is CF3 or CH3;
R is a double bond or an epoxy group;
X2 is selected from the group consisting of hydrogen and
OR1, wherein R1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R1 is an orthoester glycoside moiety of the formula:
wherein A represents a glucofuranosyl or glucopyranosyl ring;
R2 is hydrogen, lower alkyl, aralkyl, or aryl, with th proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, J-C4 alkoxy; or naphthyl; and
R3 is hydrogen or a straight or branched chain glycosidi residue containing 1-20 glycosidic units per residue, with the provis that at least one of the R1 is either a glycosidic residue or a orthoester glycoside moiety; W is CH-CH3 or 0; and V is CH2 or 0; with the proviso that both W and V are not both 0; and n===n iS either a single bond between Qa and Qb or a hydrogen atom on Qa and QD, with the proviso that wherein "===" is a single bond, then X2 is H.
34. The method of claim 33, wherein said bond between C-22 and C-23 is a single bond and at least one of the group consisting of Y2, Z2, Qa and Qb contains a fluorine atom.
EP19900916599 1989-10-04 1990-10-04 Method of accelerating wound and ulcer healing and treating periodontal disease Withdrawn EP0494995A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41678189A 1989-10-04 1989-10-04
US416781 1989-10-04

Publications (2)

Publication Number Publication Date
EP0494995A1 true EP0494995A1 (en) 1992-07-22
EP0494995A4 EP0494995A4 (en) 1993-03-17

Family

ID=23651271

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900916599 Withdrawn EP0494995A4 (en) 1989-10-04 1990-10-04 Method of accelerating wound and ulcer healing and treating periodontal disease

Country Status (3)

Country Link
EP (1) EP0494995A4 (en)
JP (1) JPH05503922A (en)
WO (1) WO1991005537A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0676951B1 (en) * 1992-12-29 2002-04-17 HOLICK, Michael F Use of vitamin d glycosides for the treatment or prevention of osteoporosis
TW422696B (en) 1995-03-20 2001-02-21 Katsuhiko Mukai Ophthalmic composition containing active vitamin D
AU5347696A (en) * 1995-11-20 1997-06-11 Kiyoshi Kita External preparation containing vitamin d or vitamin k
AU2792997A (en) * 1997-05-26 1998-12-30 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
US6187331B1 (en) 1997-06-10 2001-02-13 New Vision Co., Ltd. Composition for prophylaxis and/or treatment of dry syndrome comprising vitamin D
AU2980697A (en) * 1997-06-10 1998-12-30 New Vision Co., Ltd. Vitamin d-containing preventives and/or remedies for conjunctival/corneal xerosis
US20070299041A1 (en) * 2004-05-26 2007-12-27 Cedars-Sinai Medical Center Induction of innate immunity by vitamin d3 and its analogs
WO2006011849A1 (en) * 2004-07-28 2006-02-02 Lipopeptide Ab New use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622668A (en) * 1969-08-27 1971-11-23 Joe B Moss Method of promoting scar-free healing of skin lacerations
DE2249414A1 (en) * 1972-10-09 1974-04-25 Georg Dr Rueckheim Burn ointment contg. vitamin D3 - together with calcium phosphate, zinc oxide, olive oil and Balsam of Peru
WO1984002845A1 (en) * 1983-01-21 1984-08-02 Advanced Drug Tech Vitamin-containing skin care ointment
DE3800972A1 (en) * 1988-01-15 1989-07-27 Asche Karl W Ointment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655881A (en) * 1970-01-22 1972-04-11 Commercial Solvents Corp Method of treating burned skin
US4410515A (en) * 1981-04-01 1983-10-18 Massachusetts General Hospital Vitamin D glycosides and a method of use
US4610978A (en) * 1983-03-22 1986-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
US4521410A (en) * 1984-05-03 1985-06-04 The General Hospital Corporation Vitamin D glycosyl orthoesters
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622668A (en) * 1969-08-27 1971-11-23 Joe B Moss Method of promoting scar-free healing of skin lacerations
DE2249414A1 (en) * 1972-10-09 1974-04-25 Georg Dr Rueckheim Burn ointment contg. vitamin D3 - together with calcium phosphate, zinc oxide, olive oil and Balsam of Peru
WO1984002845A1 (en) * 1983-01-21 1984-08-02 Advanced Drug Tech Vitamin-containing skin care ointment
DE3800972A1 (en) * 1988-01-15 1989-07-27 Asche Karl W Ointment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 96, 1982, page 150, abstract 194070y, Columbus, Ohio, US; T. SAITOH et al.: "Effect of 1alpha-hydroxycholecalciferol and anabolic steroids on the healing of experimental extraction wounds, studied by microradiogram and calcium-45 autoradiogram" & SHIGAKU, 1982, 69(5), 864-897 *
CLINICAL RESEARCH, vol. 38, no. 2, April 1990 page 640A; X.A. TIAN et al.: "1,25-dihydroxyvitamin D3: A novel agent for wound healing" *
See also references of WO9105537A1 *

Also Published As

Publication number Publication date
EP0494995A4 (en) 1993-03-17
WO1991005537A1 (en) 1991-05-02
JPH05503922A (en) 1993-06-24

Similar Documents

Publication Publication Date Title
Kragballe Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903)
US5254538A (en) Method of treating periodontal disease
US5098899A (en) Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
US4610978A (en) Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
JP2664667B2 (en) Pharmaceutical composition for treating psoriasis
US5324746A (en) Method of treating damaged mucosal and epithelial tissues with misoprostol
Walsh et al. Calcifying disorders of the skin
EP0766960B1 (en) External preparations for treating dermatoses
RU2500387C1 (en) Pharmaceutical composition containing vitamin d analogue and mixed co-solvent and surfactant
Crotty et al. Ulcerative lichen planus: follow-up of surgical excision and grafting
EP0778774B1 (en) New use of prostaglandins
US8409628B2 (en) Methods and compositions for oxygenation of skin to treat skin disorders
US5037816A (en) Method of treating psoriasis
EP0494995A1 (en) Cosmetic method of inhibiting the formation of a scar
Phillips et al. Cultured allografts as an adjunct to the medical treatment of problematic leg ulcers
MXPA04009288A (en) Use of carbon-2-modified-vitamin d analogs to induce the formation of new bone.
EP0258481B1 (en) Pharmaceutical compositions for the treatment of skin diseases
US5994399A (en) Method of regenerating collagen-containing tissues with misoprostol
JP2522962B2 (en) Remedy for psoriasis
EP0536311A1 (en) Compositions comprising vitamin d precursors, analogs thereof and their use
WO2016138294A1 (en) Hesperidin-containing compositions and methods for treatment of skin disorders
McDaniel et al. Sarcoid nodules in Cushing's disease
Thornington Toenail avulsion
Kragballe Efficacy and tolerability of calcipotriol in psoriasis
JP2003226644A (en) Remedy for stomatitis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

A4 Supplementary search report drawn up and despatched

Effective date: 19930125

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR GB IT

17Q First examination report despatched

Effective date: 19940902

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19961210